Andreas Zehetner
Andreas Zehetner has been intensively engaged in various trading strategies since 2015 and is himself a passionate trend-following trader. In webinars and short video coaching sessions, he regularly presents different analysis methods. Focusing on the US market, Andreas identifies interesting breakout opportunities in leading growth stocks as part of the NEO-DARVAS strategy and based on the frameworks of legends like William O’Neil or Mark Minervini.
Latest from Andreas Zehetner
Hims & Hers: These 7 Reasons Support a Long Position
TSMC: Xiaomi Relies on 3-nm Manufacturing for Foldable Flagship with Xring O3
Xiaomi has introduced its new smartphone processor "Xring O3," which is manufactured using TSMC's...
Live Nation Entertainment: Record With 49 Million Event Attendees in Q2
Live Nation Entertainment is considered the largest live entertainment and concert events company...
CG Oncology: Bladder Cancer Specialist Sets Sails for First Approval
CG Oncology is nearing the commercialization of Cretostimogene as a new oncolytic immunotherapy for...
Nordson: This Compounder Stock is an AI Shovel Seller
Nordson (NDSN) is becoming one of the most exciting long-term stocks in the industrial sector after its...
Tenet Healthcare: US Hospital Operator Benefits from High-Margin USPI Business
Tenet Healthcare is a diversified US healthcare provider that operates around 50 acute care hospitals...
Red Violet: AI-Driven Identity Data Leads to Record Quarter
Red Violet scales significantly through high-margin identity and data analytics platforms. The IDI...
Tempus AI: Moderna Success with mRNA Cancer Vaccine Triggers Short Squeeze
Moderna success: Tempus could directly benefit from the Phase 3 study success of Moderna and Merck...
Marvell Technology: The Google Deal Increases Chances for Further Market Share
Marvell Technology (MRVL) is currently an exciting technology stock ahead of its quarterly earnings report...
Samsung: The AI Boom is Set to Pave the Way for Record Payout of $72 Billion
According to media reports, Samsung is planning a massive dividend and capital return program worth...
Halozyme Therapeutics: Record Quarter Driven by High Licensing Revenues for Subcutaneous Administration
Halozyme Therapeutics develops technologies such as the proprietary enzyme rHuPH20 (ENHANZE platform),...
Sunoco LP: Fuel Distributor Raises Annual Forecast After Record Sales of 4.1 Billion Gallons
Sunoco operates as one of the largest independent fuel wholesalers and distributors in North America....
Merck & Co.: mRNA Success With Moderna Could Give Keytruda New Momentum
Moderna and Merck impress with phase 3 study data on the combination of the mRNA cancer vaccine Intismeran...
Teledyne Technologies Becomes an AI Beneficiary of the Physical World
Teledyne Technologies (TDY) has impressed as a strong performer over the last 10 years with an average...
Lotus Bakeries: Achieving New All-Time Highs with Caramel Cookies and Healthy Snacks
The Belgian company Lotus Bakeries develops, produces, and distributes sweet snacks and bars worldwide....
Slide Insurance: AI Enables Highly Profitable Growth in High-Risk Coastal Regions
Slide Insurance utilizes AI for specialized building insurance in high-risk US coastal areas. In...
Cerebras Systems: CS-4 Is Set to Revolutionize AI Inference – Up to 30x Faster Than GPUs
The new rack-scale system CS-4 combines three WSE-3T processors and is claimed to be up to 30x faster...
These 5 Points Support a Purchase of Vertex Pharmaceuticals
I find Vertex Pharmaceuticals (VRTX) interesting for new long maneuvers for five specific reasons. ...
AMD: Potential Collaboration with Google on Next TPU Generation
According to reports, AMD is working with Google on the 10th generation of Google's proprietary AI...
Moog: Defense, Aerospace, and AI Data Centers Drive $3.3 Billion Record Order Backlog
Moog develops and manufactures high-precision motion and control systems that are used in aerospace,...
Kymera Therapeutics: Specialist in Protein Degradation Addresses a $27 Billion Market with KT-621
Kymera Therapeutics focuses on targeted protein degradation with an emphasis on developing oral therapies...